Short answer · Medically reviewed summary · Last updated: 2026-05-08
Essential Thrombocythemia was first clinically characterized in the 1930s as a distinct myeloproliferative disorder, evolving from early confusion with other blood cancers to a precisely defined genetic condition. Today, the 325 members of the DiseaseMaps community living with Essential Thrombocythemia benefit from decades of research that shifted the focus from symptom management to targeted molecular therapies. When was Essential Thrombocythemia first identified? While reports of high platelet counts appeared in early 20th-century literature, it was not until 1934 that Epstein and Goedel provided a definitive description of Essential Thrombocythemia.
2 people with Essential Thrombocythemia have shared their first-person experience on this question at DiseaseMaps.
What is the history of Essential Thrombocythemia?
History of Essential Thrombocythemia: when and how it was discovered, and the milestones in research since, medically reviewed.
Essential Thrombocythemia was first clinically characterized in the 1930s as a distinct myeloproliferative disorder, evolving from early confusion with other blood cancers to a precisely defined genetic condition. Today, the 325 members of the DiseaseMaps community living with Essential Thrombocythemia benefit from decades of research that shifted the focus from symptom management to targeted molecular therapies.
When was Essential Thrombocythemia first identified?
While reports of high platelet counts appeared in early 20th-century literature, it was not until 1934 that Epstein and Goedel provided a definitive description of Essential Thrombocythemia. Initially, the medical community struggled to differentiate it from other chronic leukemias. It was not until 1951, when William Dameshek classified it as one of the four "myeloproliferative disorders," that Essential Thrombocythemia gained its modern clinical identity as a primary disease of the bone marrow.
How has our understanding of Essential Thrombocythemia evolved?
For decades, physicians viewed Essential Thrombocythemia as a diagnosis of exclusion. This changed dramatically in 2005 with the discovery of the JAK2 mutation, which provided a clear biological marker for the disease. This genetic breakthrough transformed Essential Thrombocythemia from a clinical "best guess" into a molecularly defined diagnosis, allowing for more accurate prognostic assessments and personalized monitoring.
What are the major milestones in treatment?
The management of Essential Thrombocythemia has moved from non-specific interventions to sophisticated, risk-stratified approaches:
- Aspirin: Historically adopted to manage cardiovascular risk and microvascular symptoms.
- Hydroxyurea (Hydrea): Introduced as a standard cytoreductive therapy to lower platelet counts in high-risk patients.
- Interferon-alpha: Increasingly utilized to modify the disease course and achieve deeper molecular responses.
How has patient advocacy changed?
In the early years, patients with Essential Thrombocythemia often felt isolated due to the disease's "invisible" nature. The rise of digital platforms like DiseaseMaps has been crucial, connecting over 325 individuals to share lived experiences, which has significantly improved patient-reported outcomes and awareness of the daily challenges like chronic fatigue and bone pain.
Next steps
- Consult with a board-certified Hematologist specializing in myeloproliferative neoplasms.
- Discuss your specific genetic profile (JAK2, CALR, or MPL status) with your medical team.
- Engage with the 325 members of the DiseaseMaps community to share experiences and coping strategies.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: Essential Thrombocythemia (ORPHA:846)
- Online Mendelian Inheritance in Man (OMIM #187950)
- MPN Research Foundation
Microvascular occlusion of the toes and fingers causes digital pain; gangrene; or erythromelalgia, which is is characterized by burning pain and dusky extremity congestion
The pain increases with exposure to heat and improves with cold; a single dose of aspirin may provide relief for several days
Headache is the most common neurologic symptom. Patients also report paresthesias and episodic transient ischemic attacks; transient neurologic symptoms include the following:
Unsteadiness
Dysarthria
Dysphoria
Vertigo
Dizziness
Migraine
Syncope
Scotoma
Seizures
Thrombosis of large veins and arteries is common and may result in occlusion of the leg, coronary, and renal arteries. Other arteries may be involved, including retinal arteries. [21] Venous thrombosis of the splenic, hepatic, or leg and pelvic veins may develop. Priapism is a rare complication. Pulmonary hypertension may result from pulmonary vasculature occlusion.
Bleeding complications are as follows:
The gastrointestinal tract is the primary site of bleeding complications; approximately 40% of these patients have duodenal arcade thrombosis, resulting in sloughing of the duodenal mucosa, simulating a duodenal ulcer
Other sites of bleeding include the skin, eyes, gums, urinary tract, joints, and brain
Bleeding is usually not severe and only rarely requires transfusion
The bleeding is generally associated with a platelet count greater than 1 million/µL
Constitutional symptoms occur in 20-30% of patients. Weight loss is unusual. Other symptoms include sweating, low-grade fever, and pruritus.
Posted Aug 11, 2017 by Steve 2685
Posted Feb 7, 2019 by James 3550
